Patent application number | Description | Published |
20090130171 | High concentration gentian violet containing medical devices and methods of making same - Implantable medical devices, such as catheters, treated with a high concentration of gentian violet, and methods of preparing these medical devices are provided. | 05-21-2009 |
20100069854 | Elastomeric Devices Containing Chlorhexidine/Fatty Acid Salts Made From Fatty Acids of 12 to 18 Carbons - In a medical device, an antimicrobial agent is combined with an elastomeric polymer material. The antimicrobial agent includes at least one chlorhexidine/fatty acid salt which is a neutralization product of chlorhexidine base and a fatty acid having between 12 and 18 carbon atoms. | 03-18-2010 |
20100082097 | Article Containing Segregated Biguanide and Lewis Acid - A medical device includes a first region having a biguanide or a pharmaceutically acceptable salt thereof and a second region having a Lewis acid. | 04-01-2010 |
20100234815 | STABLE MELT PROCESSABLE CHLORHEXIDINE COMPOSITIONS - In a medical device having an antimicrobial agent, the medical device includes a base material and an amount of chlorhexidine or a pharmaceutically acceptable salt thereof disposed in the base material sufficient to reduce microbial growth. The base material is melt processed together with the chlorhexidine to generate the medical device which is substantially free of destabilized chlorhexidine. | 09-16-2010 |
20100298772 | TRANCUTANEOUS DEVICES AND KITS THAT PROVIDE CUES FOR LOCATION OF INSERTION SITE, EXIT SITE AND DEVICE PATH, AND METHODS OF USE - Transcutaneous devices are disclosed that self-provide cues for exact location of transcutaneous insertion sites, exit sites, and/or the track of the device between the sites, as are methods and kits for using the transcutaenous devices to mark the sites and track of the device and for removing location cues. | 11-25-2010 |
20120150131 | Polymer for Controlling Delivery of Bioactive Agents and Method of Use - A medical device includes a base material and chlorhexidine or a pharmaceutically acceptable salt thereof disposed in the base material sufficient to reduce microbial growth. The base material includes a polymer having a silicone monomer and a urethane monomer. | 06-14-2012 |
20120258238 | Polymer for Controlling Delivery of Bioactive Agents and Method of Use - A medical device includes a base material and chlorhexidine or a pharmaceutically acceptable salt thereof disposed in the base material sufficient to reduce microbial growth. The base material includes a polymer having a silicone monomer and a urethane monomer. To make the medical device having an antimicrobial agent, a silicone-urethane-carbonate polymer is dissolved in Dimethylformamide/Tetrahydrofuran (DMF/THF) to generate a coating solution, a chlorhexidine or a pharmaceutically acceptable salt thereof is mixed into the coating solution, a base material is coated with the coating solution, and the coating solution is dried to remove the solvent. The chlorhexidine is present in concentration sufficient to reduce microbial growth. | 10-11-2012 |
Patent application number | Description | Published |
20090253889 | POLY(TRIMETHYLENE-ETHYLENE ETHER) GLYCOLS - Block poly(trimethylene-ethylene ether) glycols are disclosed. The block poly(trimethylene-ethylene ether) glycols can be prepared by the polycondensation of 1,3-propanediol reactant and polyethylene glycol reactant. The block poly(trimethylene-ethylene ether) glycols can be used in breathable membranes, synthetic lubricants, hydraulic fluids, cutting oils, motor oils, surfactants, spin-finishes, water-borne coatings, laminates, adhesives, packaging, films and foams, fibers and fabrics. | 10-08-2009 |
20090274764 | Hollow Foam Beads for Treatment of Glioblastoma - Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow foam beads is disclosed. | 11-05-2009 |
Patent application number | Description | Published |
20130344054 | VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY - Described herein are variant, recombinant β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type β-glucocerebrosidase. Also provided herein are variant, recombinant β-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type β-glucocerebrosidase. Further described herein are variant, recombinant β-glucocerebrosidase proteins that can have amino acid variations at one or more of the following positions: 316, 317, 321 and 145. Methods of making the variant, recombinant β-glucocerebrosidase proteins are also described as well as methods of treating patients having lysosomal storage diseases. | 12-26-2013 |
20140045216 | NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSIONS AND SECRETION OF RECOMBINANT ENZYMES AND OTHER PROTEINS - Polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) are disclosed. Also disclosed are fusion proteins comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide. Also disclosed are protein expression vectors comprising a promoter operably linked to a first DNA sequence encoding a signal sequence comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) and a second DNA sequence encoding a heterologous polypeptide fused in frame to the first DNA sequence. Further disclosed are methods of producing a polypeptide comprising expressing a fusion protein comprising a polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide and recovering the heterologous polypeptide. | 02-13-2014 |
20140302001 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES - Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates. | 10-09-2014 |
Patent application number | Description | Published |
20100119502 | THERAPY REGIMENS, DOSING REGIMENS AND STABLE MEDICAMENTS FOR THE TREATMENT OF POMPE DISEASE - The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation. | 05-13-2010 |
20110070643 | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics - The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein and increase export of the protein out of the cell's endoplasmic reticulum, and increase secretion of the protein by the cell. | 03-24-2011 |
20110136151 | ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR POMPE DISEASE - Provided are in vitro, ex vivo and in vivo methods for determining whether a patient with Pompe disease will respond to treatment with a specific pharmacological chaperone. | 06-09-2011 |
20110143419 | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics - The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein and increase export of the protein out of the cell's endoplasmic reticulum, and increase secretion of the protein by the cell. | 06-16-2011 |
20110152319 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES - The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease. | 06-23-2011 |
20110189710 | TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS - Provided is a method of monitoring the treatment of Pompe disease with specific pharmacological chaperones using systemic and/or cellular surrogate markers. | 08-04-2011 |
20110212996 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES - The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease. | 09-01-2011 |
20110268721 | Therapy Regimens, Dosing Regimens And Stable Medicaments For The Treatment Of Pompe Disease - The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation. | 11-03-2011 |
20120083010 | METHOD FOR DIAGNOSING POMPE DISEASE - Provided is a method for diagnosing Pompe disease in a patient by measuring acid α-glucosidase activity in a sample from the patient. The invention also provides a method for monitoring the treatment of Pompe disease with specific pharmacological chaperones by measuring acid α-glucosidase activity in a sample from the patient. | 04-05-2012 |
20140206721 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES - The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease. | 07-24-2014 |